

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

ENZO BIOCHEM INC  
Form 8-K  
June 08, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 7, 2005

ENZO BIOCHEM, INC.

-----  
(Exact Name of Registrant as Specified in Its Charter)

NEW YORK

-----  
(State or Other Jurisdiction of Incorporation)

1-09974  
(Commission File Number)

13-2866202  
(IRS Employer Identification No.)

60 EXECUTIVE BOULEVARD  
FARMINGDALE, NEW YORK 11735

-----  
(Address of Principal Executive Offices)

(631) 755-5500

-----  
(Registrant's Telephone Number, Including Area Code)

NOT APPLICABLE

-----  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

## Edgar Filing: ENZO BIOCHEM INC - Form 8-K

On June 7, 2005, Enzo Biochem, Inc. (the "Company") issued a press release announcing it will hold a conference call to discuss its fiscal 2005 third quarter results on Thursday, June 9, 2005, at 4:45 PM ET. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and is incorporated by reference herein.

### ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c)

Exhibit No.	Description
-----	-----
99.1	Press Release of Enzo Biochem, Inc. dated June 7, 2005.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

By: /s/ Barry Weiner

-----  
Barry Weiner  
President and Chief Financial Officer

Dated: June 7, 2005

### EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of Enzo Biochem, Inc. dated June 7, 2005.